OBJECTIVES: To obtain minimum point prevalence rates for the skeletal muscle channelopathies and to evaluate the frequency distribution of mutations associated with these disorders. METHODS: Analysis of demographic, clinical, electrophysiologic, and genetic data of all patients assessed at our national specialist channelopathy service. Only patients living in the United Kingdom with a genetically defined diagnosis of nondystrophic myotonia or periodic paralysis were eligible for the study. Prevalence rates were estimated for England, December 2011. RESULTS: A total of 665 patients fulfilled the inclusion criteria, of which 593 were living in England, giving a minimum point prevalence of 1.12/100,000 (95% confidence interval [CI] 1.03-1.21). Disease-specific prevalence figures were as follows: myotonia congenita 0.52/100,000 (95% CI 0.46-0.59), paramyotonia congenita 0.17/100,000 (95% CI 0.13-0.20), sodium channel myotonias 0.06/100,000 (95% CI 0.04-0.08), hyperkalemic periodic paralysis 0.17/100,000 (95% CI 0.13-0.20), hypokalemic periodic paralysis 0.13/100,000 (95% CI 0.10-0.17), and Andersen-Tawil syndrome (ATS) 0.08/100,000 (95% CI 0.05-0.10). In the whole sample (665 patients), 15 out of 104 different CLCN1 mutations accounted for 60% of all patients with myotonia congenita, 11 out of 22 SCN4A mutations for 86% of paramyotonia congenita/sodium channel myotonia pedigrees, and 3 out of 17 KCNJ2 mutations for 42% of ATS pedigrees. CONCLUSION: We describe for the first time the overall prevalence of genetically defined skeletal muscle channelopathies in England. Despite the large variety of mutations observed in patients with nondystrophic myotonia and ATS, a limited number accounted for a large proportion of cases.
OBJECTIVES: To obtain minimum point prevalence rates for the skeletal muscle channelopathies and to evaluate the frequency distribution of mutations associated with these disorders. METHODS: Analysis of demographic, clinical, electrophysiologic, and genetic data of all patients assessed at our national specialist channelopathy service. Only patients living in the United Kingdom with a genetically defined diagnosis of nondystrophic myotonia or periodic paralysis were eligible for the study. Prevalence rates were estimated for England, December 2011. RESULTS: A total of 665 patients fulfilled the inclusion criteria, of which 593 were living in England, giving a minimum point prevalence of 1.12/100,000 (95% confidence interval [CI] 1.03-1.21). Disease-specific prevalence figures were as follows: myotonia congenita 0.52/100,000 (95% CI 0.46-0.59), paramyotonia congenita 0.17/100,000 (95% CI 0.13-0.20), sodium channel myotonias 0.06/100,000 (95% CI 0.04-0.08), hyperkalemic periodic paralysis 0.17/100,000 (95% CI 0.13-0.20), hypokalemic periodic paralysis 0.13/100,000 (95% CI 0.10-0.17), and Andersen-Tawil syndrome (ATS) 0.08/100,000 (95% CI 0.05-0.10). In the whole sample (665 patients), 15 out of 104 different CLCN1 mutations accounted for 60% of all patients with myotonia congenita, 11 out of 22 SCN4A mutations for 86% of paramyotonia congenita/sodium channel myotonia pedigrees, and 3 out of 17 KCNJ2 mutations for 42% of ATS pedigrees. CONCLUSION: We describe for the first time the overall prevalence of genetically defined skeletal muscle channelopathies in England. Despite the large variety of mutations observed in patients with nondystrophic myotonia and ATS, a limited number accounted for a large proportion of cases.
Authors: H Papponen; T Toppinen; P Baumann; V Myllylä; J Leisti; H Kuivaniemi; G Tromp; R Myllylä Journal: Neurology Date: 1999-07-22 Impact factor: 9.910
Authors: W G Feero; J Wang; F Barany; J Zhou; S M Todorovic; R Conwit; G Galloway; I Hausmanowa-Petrusewicz; A Fidzianska; K Arahata Journal: Neurology Date: 1993-04 Impact factor: 9.910
Authors: G Fouad; M Dalakas; S Servidei; J R Mendell; P Van den Bergh; C Angelini; K Alderson; R C Griggs; R Tawil; R Gregg; K Hogan; P A Powers; N Weinberg; W Malonee; L J Ptácek Journal: Neuromuscul Disord Date: 1997-01 Impact factor: 4.296
Authors: T M Miller; M R Dias da Silva; H A Miller; H Kwiecinski; J R Mendell; R Tawil; P McManis; R C Griggs; C Angelini; S Servidei; J Petajan; M C Dalakas; L P W Ranum; Y H Fu; L J Ptácek Journal: Neurology Date: 2004-11-09 Impact factor: 9.910
Authors: Véronique Bissay; Sophie C H Van Malderen; Kathelijn Keymolen; Willy Lissens; Uschi Peeters; Dorien Daneels; Anna C Jansen; Gudrun Pappaert; Pedro Brugada; Jacques De Keyser; Sonia Van Dooren Journal: Eur J Hum Genet Date: 2015-06-03 Impact factor: 4.246
Authors: Bas C Stunnenberg; Samantha LoRusso; W David Arnold; Richard J Barohn; Stephen C Cannon; Bertrand Fontaine; Robert C Griggs; Michael G Hanna; Emma Matthews; Giovanni Meola; Valeria A Sansone; Jaya R Trivedi; Baziel G M van Engelen; Savine Vicart; Jeffrey M Statland Journal: Muscle Nerve Date: 2020-05-27 Impact factor: 3.217
Authors: Valeria A Sansone; James Burge; Michael P McDermott; Patty C Smith; Barbara Herr; Rabi Tawil; Shree Pandya; John Kissel; Emma Ciafaloni; Perry Shieh; Jeffrey W Ralph; Antony Amato; Steve C Cannon; Jaya Trivedi; Richard Barohn; Brian Crum; Hiroshi Mitsumoto; Alan Pestronk; Giovanni Meola; Robin Conwit; Michael G Hanna; Robert C Griggs Journal: Neurology Date: 2016-02-10 Impact factor: 9.910